Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists.
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
27
09
2019
accepted:
12
08
2020
revised:
17
06
2020
pubmed:
28
8
2020
medline:
23
11
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
Over the past decade, pharmacogenetics (PGx) became an essential tool for personalized medicine although its clinical implementation is still limited. We aimed to assess the current level of knowledge, applications, and expectations of Flemish pharmacists and physicians towards PGx and determine the factors that influence healthcare professionals' knowledge of PGx, aiming to guide future implementation initiatives. A web-based cross-sectional survey was conducted from 8 March 2019 to 8 April 2019, targeting pharmacists, physicians, and trainees of both professions. Ten questions were used to assess the participants' knowledge about PGx. Multivariable linear regression was used to assess the association of profession, experience, practice setting, and prior education with the level of PGx knowledge. In total, 201 Flemish healthcare providers participated, including 100 pharmacists, 73 physicians, and 28 trainees. The majority (78%) of participants were unfamiliar with the basic principles of PGx and its application in clinical practice. The mean percentage of correct answers achieved for the knowledge assessment questions was 34%. Only 9% had counseled patients, while 8% assisted other healthcare professionals on PGx tests the past year. Participants' PGx knowledge was significantly affected by their profession, practice setting, and level of prior education independent of years of experience. These findings provide insight into factors affecting the knowledge of PGx and the current level of PGx implementation in Flemish clinical practice. This may form a basis for developing educational initiatives to enhance the clinical application of PGx in Flanders.
Identifiants
pubmed: 32848197
doi: 10.1038/s41397-020-00180-x
pii: 10.1038/s41397-020-00180-x
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-84Références
Stewart A, Brice P, Burton H, Pharoah P, Sanderson S, Zimmern R. Genetics, Health Care and Public Policy: An Introduction to Public Health Genetics. Cambridge University Press, Cambridge; 2007.
Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82:388–94.
doi: 10.1111/j.1399-0004.2012.01908.x
Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond Ser B, Biol Sci. 2005;360:1563–70.
doi: 10.1098/rstb.2005.1685
Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharm Pharmacother. 2013;4:S73–7.
doi: 10.4103/0976-500X.120957
MacKenzie M, Hall R. Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. Can J Anaesth. 2017;64:45–64.
doi: 10.1007/s12630-016-0748-1
Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N. Engl J Med. 2003;348:538–49.
doi: 10.1056/NEJMra020526
Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464–8.
doi: 10.1038/nature02626
Kudzi W, Adjei GO, Ofori-Adjei D, Dodoo AN. Pharmacogenetics in Ghana: reviewing the evidence. Ghana Med J. 2011;45:73–80.
doi: 10.4314/gmj.v45i2.68932
Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four—G6PD deficiency: global distribution, genetic variants and primaquine therapy. In: Hay SI, Price R, Baird JK, editors. Advances in Parasitology. 81: Academic Press, United Kingdom; 2013. pp. 133–201.
Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;310:584–6.
doi: 10.1016/S0140-6736(77)91430-1
Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442–6.
doi: 10.1038/331442a0
Wheeler DA, Wang L. From human genome to cancer genome: the first decade. Genome Res. 2013;23:1054–62.
doi: 10.1101/gr.157602.113
Makalowski W. The human genome structure and organization. Acta Biochim Pol. 2001;48:587–98.
doi: 10.18388/abp.2001_3893
Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm. 2009;66:625–37.
doi: 10.2146/ajhp080170
Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics 2009;19:559–62.
doi: 10.1097/FPC.0b013e32832e0e97
Barbarino JM, Kroetz DL, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics. 2015;25:205–21.
doi: 10.1097/FPC.0000000000000118
Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22:159–65.
doi: 10.1097/FPC.0b013e32834d4962
Weitendorf F, Reynolds KK. The pharmacist’s perspective on pharmacogenetics implementation. Clin Lab Med. 2016;36:543–56.
doi: 10.1016/j.cll.2016.05.009
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Davila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharm Ther. 2017;101:341–58.
doi: 10.1002/cpt.602
Drozda K, Pacanowski MA, Grimstein C, Zineh I. Pharmacogenetic labeling of FDA-approved drugs: a regulatory retrospective. JACC Basic Transl Sci. 2018;3:545–9.
doi: 10.1016/j.jacbts.2018.06.001
Albassam A, Alshammari S, Ouda G, Koshy S, Awad A. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. PLoS ONE. 2018;13:e0203033.
doi: 10.1371/journal.pone.0203033
Cecchin E, Roncato R, Guchelaar HJ, Toffoli G. Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. an Horizon2020 Program to drive pharmacogenomics into clinical practice. Curr Pharm Biotechnol. 2017;18:204–9.
doi: 10.2174/1389201018666170103103619
Bank PCD, Swen JJ, Guchelaar H-J. A nationwide survey of pharmacists’ perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. Pharmacogenomics 2017;18:215–25.
doi: 10.2217/pgs-2016-0138
AlEjielat R, Ejielat Z, Andrawes S, Mhaidat NM. An evaluation of the knowledge, opinions, expectations and concerns toward pharmacogenomics among Jordanian pharmacists. Personalized Med. 2016;13:143–54.
doi: 10.2217/pme.15.50
Schwartz EJ, Issa AM. The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. Per Med. 2017;14:27–35. https://doi.org/10.2217/pme-2016-0063 .
Tuteja S, Haynes K, Zayac C, Sprague JE, Bernhardt B, Pyeritz R. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Personalized Med. 2013;10:793–800.
doi: 10.2217/pme.13.85
Bannur Z, Bahaman S, Salleh M, Kek TL. Pharmacogenomics based practice in Malaysia: the attitude, knowledge and adoption by the healthcare professionals. Int Med J Malays. 2014;13:41–50.
Roederer MW, Van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Personalized Med. 2012;9:1927.
doi: 10.2217/pme.11.87
Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry Zgheib N. Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. Br J Clin Pharmacol. 2019;85:2076–88. https://doi.org/10.1111/bcp.13999 .
Stanek EJ, Sanders CL, Taber KAJ, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US Physicians: Results of a Nationwide Survey. Clin Pharmacol Ther. 2012;91:450–8. https://doi.org/10.1038/clpt.2011.306 .
Kadafour M, Haugh R, Posin M, Kayser S, Shin J Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics. 2009;10:1853–60. https://doi.org/10.2217/pgs.09.117 .
OECD. Health Care Resources: Pharmacists 2019. Accessed 13 Sep 2019. https://stats.oecd.org/index.aspx?queryid=30178# .
EAHP. Belgian Association of Hospital Pharmacists 2012. Accessed 13 Sep 2019. https://www.eahp.eu/members/belgium .